CSPC Pharmaceutical Group Limited

DB:CVG Stock Report

Market Cap: €6.9b

CSPC Pharmaceutical Group Past Earnings Performance

Past criteria checks 2/6

CSPC Pharmaceutical Group has been growing earnings at an average annual rate of 8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 8% per year. CSPC Pharmaceutical Group's return on equity is 14.3%, and it has net margins of 17%.

Key information

8.0%

Earnings growth rate

8.2%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate8.0%
Return on equity14.3%
Net Margin17.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How CSPC Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:CVG Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2430,2715,1579,9485,032
30 Jun 2431,6545,92710,3035,069
31 Mar 2432,3806,05710,8724,992
31 Dec 2331,4505,87310,3304,830
30 Sep 2331,3066,11810,4104,744
30 Jun 2331,4076,09210,9734,406
31 Mar 2331,1166,11611,1774,093
31 Dec 2230,9376,09111,5103,987
30 Sep 2230,7215,73811,9153,845
30 Jun 2229,6555,50911,6113,704
31 Mar 2229,0075,53811,7003,643
31 Dec 2127,8675,60511,4533,433
30 Sep 2126,3695,97710,7473,132
30 Jun 2126,1755,90810,7033,050
31 Mar 2125,5515,47210,3323,013
31 Dec 2024,9425,16010,3232,890
30 Sep 2024,5584,42110,5222,765
30 Jun 2023,5154,15010,2872,511
31 Mar 2022,7353,92210,0502,108
31 Dec 1922,1033,7149,4612,000
30 Sep 1921,3353,6258,8871,928
30 Jun 1920,1353,4548,2021,725
31 Mar 1918,8353,2947,4261,543
31 Dec 1817,7173,0816,8411,342
30 Sep 1816,8772,9056,3371,346
30 Jun 1815,7292,7345,664973
31 Mar 1813,9592,4434,839912
31 Dec 1712,8772,3074,178679
30 Sep 1712,2032,1953,747277
30 Jun 1711,6592,0683,410282
31 Mar 1711,3831,9793,2030
31 Dec 1611,0751,8812,9920
30 Sep 1610,4391,7112,7250
30 Jun 1610,1181,6072,5760
31 Mar 169,6561,4732,4190
31 Dec 159,5451,3952,3470
30 Sep 159,2841,3052,2020
30 Jun 159,0721,1922,0450
31 Mar 158,9191,1261,9380
31 Dec 148,7621,0151,8710
30 Sep 148,4238961,7480
30 Jun 148,1978491,6860
31 Mar 148,0018141,6270
31 Dec 137,7687601,5000

Quality Earnings: CVG has high quality earnings.

Growing Profit Margin: CVG's current net profit margins (17%) are lower than last year (19.5%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CVG's earnings have grown by 8% per year over the past 5 years.

Accelerating Growth: CVG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: CVG had negative earnings growth (-15.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (25.4%).


Return on Equity

High ROE: CVG's Return on Equity (14.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CSPC Pharmaceutical Group Limited is covered by 50 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wai Chak YuenBOCI Research Ltd.
Sharon ShiBOCI Research Ltd.
Ethan CuiBofA Global Research